Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma | Zendy

Julien Edeline | Zendy; Marine Gilabert | Zendy; Étienne Garin | Zendy; Éveline Boucher | Zendy; JeanLuc Raoul | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma

Author(s) -

Julien Edeline,

Marine Gilabert,

Étienne Garin,

Éveline Boucher,

JeanLuc Raoul

Publication year - 2014

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000343878

Subject(s) - hepatocellular carcinoma , medicine , sorafenib , microsphere , radiology , carcinoma , selective internal radiation therapy , nuclear medicine , oncology , chemical engineering , engineering

Yttrium-90 (Y90) radioembolization is an emerging strategy to treat liver malignancies, and clinical data supporting its use have accumulated in recent years. Y90-radioembolization has shown clinical effectiveness in intermediate and advanced hepatocellular carcinoma, with a favorable safety profile. Retrospective data show similar levels of effectiveness to transarterial chemoembolization in intermediate hepatocellular carcinoma, with some evidence of better tolerance. While phase 3 studies comparing Y90-radioembolization to chemoembolization in intermediate hepatocellular carcinoma would be difficult to conduct, studies comparing or combining Y90-radioembolization with sorafenib are under way. Questions also remain about the most suitable modalities for defining the dose to administer. Phase 3 studies are under way to clarify the place of Y90-radioembolization in the algorithm of HCC treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research